Alhambra, CA, United States of America

Xiaogang Hou

This inventor holds 1 USPTO granted patent and 1 published patent application, plus 1 CIPO patent. Top assignee: Dna Vec Research Inc.. Active years: 2012.

USPTO Granted Patents = 1 


Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2012

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Xiaogang Hou in Gene Therapy

Introduction

Xiaogang Hou is an accomplished inventor based in Alhambra, CA (US). He has made significant contributions to the field of gene therapy, particularly through his innovative work with Paramyxovirus vectors. His research focuses on the effective transfer of angiogenic genes into individual tissues, which has important implications for treating ischemic conditions.

Latest Patents

Xiaogang Hou holds a patent for a "Paramyxovirus vector encoding angiogenesis gene and use thereof." This invention provides Paramyxovirus vectors that encode angiogenic genes, enabling effective gene transfer into ischemic tissues. The FGF2 gene, when transferred into ischemic tissues in vivo, induces the expression of angiogenic genes without causing edema and prevents necrosis due to ischemia. The vectors developed by Hou are particularly suitable for targeted gene therapy aimed at ischemic tissues.

Career Highlights

Xiaogang Hou is associated with Dna Vec Research Inc., where he continues to advance his research in gene therapy. His work has garnered attention for its potential to improve treatment outcomes for patients suffering from ischemic conditions.

Collaborations

Some of his notable coworkers include Yoshikazu Yonemitsu and Katsuo Sueishi, who contribute to the collaborative efforts in research and development at Dna Vec Research Inc.

Conclusion

Xiaogang Hou's innovative work in gene therapy, particularly with Paramyxovirus vectors, showcases his commitment to advancing medical science. His contributions have the potential to significantly impact the treatment of ischemic diseases.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…